Study To Focus On Diagnostic Test Kits For Pancreatic Cancer
Diagnostic Test Kits For Pancreatic Cancer
Response Genetics will conduct a two-year research study to develop a diagnostic test kit for pancreatic cancer.
The study will combine patient outcomes data with genetic information that it extracts from archival formalin-fixed paraffin-embedded (FFPE) pancreatic tissue samples. The results could potentially lead to the development of assays and diagnostic tests for pancreatic cancer.
The study will be conducted in collaboration with UCSF, which will provide the tissue samples. Response Genetics will assume the administrative costs of the research.
Margaret A. Tempero, Deputy Director, UCSF Comprehensive Cancer Center, and Professor, Division of Medical Oncology, UCSF Department of Medicine, will serve as Principal Investigator of the project.
"We are delighted to be collaborating with Dr. Tempero, one of the nation's leading experts in pancreatic cancer, on this very important research project," said Kathleen Danenberg, President and CEO of Response Genetics. "Diagnostics tests emerging from this collaboration would help physicians tailor treatment to the individual by using genetic information to identify patients who would most benefit from surgery or chemotherapy and radiation."
Pancreatic cancer is the fifth-leading cause of cancer deaths in the United States. According to the American Cancer Society, approximately 37,170 people in the United States will be diagnosed with pancreatic cancer this year and an estimated 33,370 deaths will occur from pancreatic cancer this year in the United States.